Improving affordability of new Essential Cancer Medicines
Lancet Oncol
.
2019 Aug;20(8):1052-1054.
doi: 10.1016/S1470-2045(19)30459-0.
Epub 2019 Jul 11.
Authors
Ellen 't Hoen
1
,
Salomé Meyer
2
,
Patrick Durisch
3
,
Wilbert Bannenberg
4
,
Katrina Perehudoff
5
,
Tim Reed
6
,
Melissa J Barber
7
Affiliations
1
Medicines Law and Policy and University Medical Centre Groningen, Global Health Unit, Groningen, Netherlands.
2
Cancer Alliance South Africa, Cape Town, 7700, South Africa. Electronic address:
[email protected]
.
3
Public Eye, Switzerland, Lausanne, Switzerland.
4
Pharmaceutical Accountability Foundation, Bergeijk, Netherlands.
5
Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
6
Health Action International, Amsterdam, Netherlands.
7
Harvard University, Cambridge, MA, USA.
PMID:
31303433
DOI:
10.1016/S1470-2045(19)30459-0
No abstract available
MeSH terms
Antineoplastic Agents / economics*
Developing Countries
Drugs, Essential / economics*
Health Services Accessibility*
Humans
Poverty
Substances
Antineoplastic Agents
Drugs, Essential